Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Effect in Pulmonary Hypertension
IRCT20241014063361N1Phase 3Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in pulmonary hypertension (PH), sponsored by Baqiyatallah University of Medical Sciences. Started Nov 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on IRCT20241014063361N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241014063361N1.